The study is a follow-up of the study "Coronavirus in pregnant patients and their clinical outcomes – results of a case-control study" conducted by R.Kadriu et al (2023) in which,in addition to the pregnant patients whose outcome is now being investigated,a control group of patients who were not pregnant,conducted with pregnant patients and a control group that were non-pregnant patients.This study was conducted 6 months after the discharge of the patients and their newborns,and highlights the impact of COVID-19 on their health as well as the health of the newborns. The aim of the study is to follow up the patients after 6 months of their hospitalization as COVID-19 patients and after their delivery.In the COVID study, none of the health indicators showed statistically significant differences between the population before and after hospitalization.Patient data were collected at the case level summarized in their respective groups.For secondary objectives, several comparative analyzes were performed regarding comorbidity-related parameters and available risk factors.A significance level (α) of 0.05 was used for statistical significance. While these results may be reassuring regarding the stability of health status, one should be aware of the limitations of the study, including sample size and specific population characteristics.Full article

Introduction: Cerebral venous thrombosis is a rare type of stroke caused by partial or complete occlusion of cerebral venous sinuses. Current guidelines recommend the administration of Low Molecular Weight Heparin (LMWH) during the acute phase and oral Vitamin K antagonists (VKAs) such as warfarin for 3-12 months. Direct Oral Anticoagulants (DOACs) are an attractive alternative to VKAs as therapy for CVT, for its safety and efficacy as anticoagulation therapy for deep venous thrombosis or pulmonary embolism. Method: This systematic review is written based on PRISMA guidelines with electronic search performed on various databases for journals published from June 1, 2018 to June 1, 2023. Results: We found four studies fulfilling the inclusion criteria, with four randomized controlled studies presenting 179 CVT patients treated with DOAC and 150 patients treated with standard therapy. DOACs used in reviewed studies are Dabigatran and Rivaroxaban. Discussion: Administration of DOACs as anticoagulation therapy in patients with CVT presents better recanalization rate with no significant differences in efficacy compared with VKAs, along with a better safety profile through similar mortality rate across two groups. Conclusion: DOACs as long-term anticoagulation therapy in patients with CVT has better efficacy along with a similar safety profile compared to VKA.Full article

The decision to choose between onsite and offsite construction is important in the effort toward sustainable construction. Offsite construction is often promoted as an environmentally friendly approach to construction operations. However, previous studies have shown that there is a lack of clarity on the environmental trade-offs between onsite and offsite construction. Factors that can affect the decision to build onsite or offsite include the availability of a local offsite manufacturing facility, the distance of the offsite factory to the final place of use, the proximity of the site to the local supply of material and labor, etc. This study provides a framework to apply the system dynamic modeling technique to evaluate how various factors can affect the environmental impact of the building construction phase (for onsite or offsite construction methods). The system dynamic model (using Vensim software) that was developed provides a platform that allows users to input variables such as the distance that is expected for transportation of labor, material, and equipment to both the onsite facility and the offsite construction location, factors associated with the use of equipment for construction, the distance needed for transportation of building panels or modules from the offsite facility to the final site, etc. Among other things, the model showed that an increase in the distance from the offsite yard to the final construction site increases the total impacts of transportation of completed modules. An increase in the number of trips for the transportation of material to the onsite construction location increases the total impact of onsite construction. In terms of the environmental impact of construction, none of the two methods of construction gives an absolute superiority over the other. The environmental performance of offsite and onsite depends on various associated factors. It is recommended that building practitioners review various factors that are peculiar to their projects to make an informed decision on the best construction methods.Full article

The global pharmaceutical supply chain plays a crucial role in ensuring the timely and safe delivery of medicines to patients worldwide. However, the increasing presence of counterfeit drugs within this supply chain poses a significant and growing risk to public health, patient safety, and the integrity of the pharmaceutical industry. Counterfeit drugs—medications that are fraudulently manufactured, mislabeled, or contain incorrect or harmful ingredients—are a major concern as they can lead to ineffective treatments, adverse health effects, and even death. Despite stringent regulatory frameworks and advanced technological solutions, counterfeit drugs continue to infiltrate legitimate supply chains due to factors such as the complexity of the distribution system, global trade practices, and inadequate enforcement in certain regions. This manuscript explores the primary causes behind the proliferation of counterfeit drugs in pharmaceutical distribution, the associated risks, and the multifaceted approaches required to address this growing threat. It discusses the importance of regulatory measures, including international cooperation and stronger compliance frameworks, as well as the role of emerging technologies like serialization, blockchain, and RFID in ensuring traceability and product authenticity. By focusing on the integration of these technologies, the paper also highlights the potential of innovative solutions to enhance transparency, reduce vulnerabilities, and protect the integrity of pharmaceutical supply chains. Additionally, it emphasizes the importance of public awareness campaigns and collaboration between key stakeholders, including pharmaceutical manufacturers, distributors, regulators, and healthcare providers, in creating a more secure and trustworthy pharmaceutical distribution ecosystem. Through a comprehensive exploration of these strategies, this manuscript aims to provide a roadmap for mitigating the risks posed by counterfeit drugs and ensuring the safety and efficacy of medicines for consumers worldwide.Full article